Supreme delivers record £235m revenue in FY25, boosted by acquisitions
Investors hate uncertainty, and unfortunately there's a lot at the moment. That said, despite the volatility, many UK smallcaps are not directly impacted by President Trump's trade tariffs.
Indeed, one could even argue that 's quality, yet affordable everyday FMCG products might actually be a net beneficiary in an environment where household discretionary spend is under pressure. Plus, following last year's complementary acquisitions of Clearly Drinks (£15m) and Typhoo Tea (£10.2m), there's plenty of cost and sales synergises to realise over the next few years, alongside new product launches.
Ok, so how is the business performing?
Well, encouragingly today, the company released an 'in line' trading update for the Mar'25 year-end, saying that it had delivered record turnover and adjusted EBITDA of £235.0m (+6.2%, FY24 £221.2m) and at least £40.0m (+5%, FY24 £38.1m) respectively - ending the period with net cash, and being "confident in its prospects".
Additionally, with these two drinks brands now onboard, there's a nice product balance with non-vape revenues now representing approx half (annualised £120m) of the group.
Sure, going forward, the 1st June ban on disposable vapes is likely to affect the firm's UK distribution of Chinese brands ElfBar and Lost Mary (est FY26 impact -£18m sales, -£3.9m EBIT). Yet, this is set to be partly offset by the rest of the business, which is economically resilient, meaning overall FY26 sales and EBITDA are anticipated to come in at £231m (-£9m YoY) and £36.5m (-£3.5m YoY) respectively. Thus putting the stock at 167p on modest EV/EVITDA and PE multiples of 5.5x and 8.4x, with Equity Development valuing at 225p/share.
Final FY25 results are scheduled for Tuesday 1st July 2025.
Follow News & Updates from Supreme plc:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.